Loading...
Symbols:
Loading...
Symbols:
Alnylam Pharmaceuticals Inc. (ALNY)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Alnylam Pharmaceuticals Inc. (ALNY)
30 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on ALNY
- Ohad Hammer(3)
- Mike Havrilla(3)
- Centient Biotech Investor(3)
- ChinaBio Today(2)
- Eben Tessari (2)
Most popular authors
(tracked in watchlists)
- Andrew Wilkinson(336)
- Stockerblog (170)
- Mike Havrilla(105)
- Don Dion(104)
- ChinaBio Today(61)
Most commented on authors
- Ohad Hammer(17)
- Michael Steinberg (7)
- Derek Lowe(7)
- Michael Shulman(4)
- Mike Havrilla(3)
- Can MicroRNA Reverse Heart Disease?
- Four Biotechs at Attractive Entry Points
- Even Fatter Yields for Pfizer; M&A Targets in the Sector
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Alnylam and RNAi: The Truth Hurts
- Alnylam Pharmaceuticals: A Falling Star
- My Model Biotech Picks: What's Hot and What's Not
- Investing in miRNA: Beware the Hype, Follow the Money
- Can Takeda (or Roche, or Merck, or...) Afford to Ignore RNAi?
- Wednesday Options Outlook: AIG, LM, RL, XRAY, ALNY, EXPE, MAS, XLF, CSCO
- Alnylam and Takeda Form Alliance In RNAi
- Six Significant Gene Therapy Stocks
- Isis Pharmaceuticals Panic Overdone
- Rosetta Genomics: Mining Genes From Junk (Part II)
- China Biotech in Review: Approvals, Deals and Company News
- Alnylam Signs First Transaction with China Biotech on RNAi Research Products
- Alnylam Stakes Claim to 1st Human Demo of Activity for RNAi Therapy
- 2007 Biotech Performance Review
- PBE: Large Biotech Meets Small Biotech
- RNAi: Seeking a Cure at the Flick of a Switch
- RNA Interference Stocks: Invest At Your Own Risk
- Gaming Rules For Trading Biotech Stocks
- Alnylam Pharmaceuticals Soars on Roche Holding Collaboration
- Biotech Day In Review: CuraGen Gets $155 Million For Gene Sequence Division
- Biotech Day In Review: Amgen Hit with SEC Investigation
- Eye on Alnylam: Silencing the Gene
- Best Stem Cell Plays: Osiris and Aastrom
- Biotech Stocks Review: Amphora Sells Oncology Program to Genentech
- Alnylam, CytRx Gain by Moving into RNAi
- Biotech IPO: Highlights from Rosetta Genomics' F1 Filing
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »